Floatz Rating
C36/100
Confidence
Indicative
Sponsor
Spectrum Pharmaceuticals, Inc
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
21Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04172597CT.gov A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Poziotinib (this asset) | Spectrum Pharmaceuticals, Inc | P2 | C · 36 |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Enzastaurin | Denovo Biopharma LLC | P3 | BB |
| Carboplatin | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Poziotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | CC · 41 |
| Breast Cancer | — | P2 | CC · 40 |
| Lung Cancer | — | P2 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Poziotinib in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/poziotinib-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →